Sunday 25 September 2016

Faculté de Pharmacie
3, rue du Professeur Laguesse
BP83 - 59006 - Lille Cedex
Tél. : +33 (0)3 20 96 40 40
Fax : +33 (0)3 20 95 90 09
mailContact

CONTACT

Université Lille Nord de France
INSERM U1008
College of Pharmacy
3, rue du Professeur Laguesse
59006 Lille, France

Tel: +33-3-20964975
Fax: +33-3-20964995
Télécharger le fichiercontact

CONFERENCES

4th Congress on Innovation in Drug Delivery

September 25-28, 2016, Antibes-Juan-les-Pins, France

Lien externe - Ouverture dans une nouvelle fenêtrehttps://idd2016.sciencesconf.org

 

2nd European Conference on Pharmaceutics: "Novel Dosage Forms, Innovative Technologies"

April 3-4, 2017, Krakow, Poland

Lien externe - Ouverture dans une nouvelle fenêtrehttp://www.europeanmeeting.org/home

 

Agenda

September - 2016
Su Mo Tu We Th Fr Sa
  01 02 03
04 05 06 07 08 09 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
26 27 28 29 30  

INSERM U1008: Controlled Drud Delivery Systems and Biomaterials

Numerous drug candidates fail to show in vivo efficacy. This can be attributed to their physicochemical properties and / or pharmacokinetics / pharmacodynamics, in particular poor aqueous solubility, poor permeability across biological barriers, rapid drug elimination out of the living body and/or narrow therapeutic windows. Even if the substance exhibits an ideal chemical structure allowing for optimal therapeutic effects, the therapy fails if the drug cannot reach its site of action in the human body.

Our aim is to overcome these restrictions and to develop novel types of advanced drug delivery systems and biomaterials allowing for an accurate control of the resulting drug release kinetics during periods ranging from a few minutes up to several years. Thus, the drug can effectively be protected in the human body and potentially administered directly at its site of action. We work on different types of systems, in particular:

• Coated pellets which are orally administered and allow for site specific drug delivery to the colon. This is of major benefit for the treatment of inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis

• Biodegradable microparticles for parenteral administration, especially for the treatment of brain diseases (e.g., cancer and neurodegenerative disorders)

• Lipid implants for the controlled delivery of fragile protein drugs (e.g., growth factors)

• Drug eluting stents with improved biocompatibility

• Implants releasing antibiotics and anesthetics in a time controlled manner for dental surgery

• Scaffolds releasing incorporated drugs at a pre-determined rate for bone substitution in facial surgery.

INSERM U1008 - Key methods & aims of the research group

We prepare the different types of advanced drug delivery systems and biomaterials using a broad range of techniques, for instance via direct compression of drug-polymer blends, fluidized bed coating, extrusion, and freeze drying. The devices are thoroughly characterized in vitro with a large variety of physicochemical and biological methods (e.g., in vitro drug release measurements, differential scanning calorimetry, size exclusion chromatography, mechanical analysis, cell culture tests, biocompatibility and bioerosion studies). Furthermore, the pharmacokinetics and pharmacodynamics of the drugs are determined in vivo (animal models and clinical trials).

Based on these experimental results, novel mathematical theories are developed allowing for the elucidation of the underlying drug release mechanisms and for the quantitative prediction of the effects of formulation and processing parameters on the resulting drug release kinetics. Thus, the optimization of the novel drug delivery systems and biomaterials can be facilitated. Furthermore, we establish in vitro – in vivo correlations, in particular with respect to the drug release kinetics. This allows to reduce the number of required animal studies and to improve the safety of the novel pharmaco-therapies.

 

 





Page updated on 08/08/2016 (15h29)
 
Flux rss actualités